IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Asston Pharmaceuticals IPO is a book build IPO listing on BSE SME exchange. The company is based in Mumbai and caters to Pharmaceutical sector. Sobhagya Capital Options is the merchant banker of Asston Pharmaceuticals IPO. It is a SME UPCOMING IPO which filed its Draft Red Herring Prospectus (DRHP) on 16th January 2025.
Asston Pharmaceuticals IPO posted revenues of Rs 33.39 crores and PAT of Rs 5.05 crores in FY25 on annualised basis.Financial results of Asston Pharmaceuticals IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Asston Pharmaceuticals IPO PAT Margin is 16.30%, ROCE (Return on Capital Employed) is 44.47% as per latest financial. The below table shows Asston Pharmaceuticals IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Asston Pharmaceuticals IPO is Rs [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Asston Pharmaceuticals IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Asston Pharmaceuticals IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Asston Pharmaceuticals IPO is ₹[●] Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Asston Pharmaceuticals IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Asston Pharmaceuticals IPO reported revenue of ₹33.39 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Asston Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
Asston Pharmaceuticals recorded an EBITDA of ₹ 5.69 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Asston Pharmaceuticals Profit After Tax (PAT) is ₹5.06 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 31.02 Cr.
EBITDA Margin:
18.33
%
Net Worth: ₹ 9.77 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Asston Pharmaceuticals operates in Pharmaceutical and . The Issue is listed on BSE SME in Apr, 2025. Asston Pharmaceuticals IPO size was with Issue price of .
Merchant Banker(s) of Asston Pharmaceuticals IPO: Sobhagya Capital Options Limited
Asston Pharmaceuticals IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Asston Pharmaceuticals IPO listed at a listing price of against the offer price of .
The current market price of Asston Pharmaceuticals is .
Why Us?
